Inhibition of factor B, the alternative complement pathway and methods related thereto

US8652475B2 · kind B2 · utility

Assignees

• MUSC Foundation for Research Development · US
• National Jewish Health · US
• The Regents of the University of Colorado, a Body Corporate · US

Inventors

• Vernon Michael Holers · Denver, US
• Joshua M. Thurman · Greenwood Village, US
• Christian Taube · Wassenaar, NL
• Erwin Gelfand · Englewood, US
• Gary Gilkeson · Charleston, US

Key dates

• Filing date: Aug 3, 2007
• Grant date: Feb 18, 2014
• Expiry date: Sep 13, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.